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Brucellosis is a zoonosis with a worldwide distribution, espe-
cially in the Mediterranean basin, the Arabian peninsula, the
Indian subcontinent, Mexico and Central and South America
[1]. It is a systemic disease, and almost every organ can be
affected. The infection usually manifests itself as a febrile
syndrome with no apparent focus, chills, sweating, arthralgia,
and myalgia. About 30% of patients suffer from some localiza-
tion, most commonly bone and joint involvement [2]. Cardi-
ovascular complications are rare, occurring in less than 2% of
patients with brucellosis; they include endocarditis, myocarditis,
and pericarditis [3]. Brucella endocarditis accounts for the
majority of deaths related to brucellosis [4]. The treatment
for brucella endocarditis has not been well established, basically
because of the low number of reported cases. We herein report
our experience with four cases of brucella endocarditis, discuss
treatment options, and review the pertinent literature.
Between 1987 and 1999, four patients were diagnosed as
having brucella endocarditis at Hamad Medical Corporation.
Diagnosis was based on the presence of vegetations on echo-
cardiography, and further supported by positive blood culture,
culture of infected tissue growing Brucella organisms, or a high
brucella serologic titer of over 1 : 320 dilution. The following
data were collected: age, sex, nationality, occupation, raw milk
ingestion, symptoms, physical findings at presentation, total
white blood cell count, erythrocyte sedimentation rate, serol-
ogy, echocardiography, blood culture, culture of infected tissue,
treatment, complications, and outcome.
The age of the patients ranged between 29 and 40 years.
All patients complained of fever. Other symptoms included
anorexia, cough, and night sweats. One patient had hemiparesis.
The duration of symptoms ranged between 2 weeks and 9
months. All patients had a history of raw milk ingestion. Three
patients had a history of valvular heart disease, and had mechan-
ical valvular prostheses. Physical findings on admission included
fever in all patients, and splenomegaly and right-sided hemi-
paresis in one patient each. None of the patients had evidence
of heart failure on presentation or during follow-up.
All patients had normal white blood cell counts. The ery-
throcyte sedimentation rate was elevated in all patients
(range 33–96 mm/h). Blood culture grew Brucella organisms
in three patients. The brucella antibody titer was elevated in
three patients (range 1280–5120). In one patient, brucella
serology was negative in spite of repeated testing; however,
the blood culture was positive in this patient. Transesophageal
echocardiography showed vegetations in all patients. It also
showed paravalvular leak in two patients and an abscess in one
patient.
One patient with native valve brucella endocarditis was
treated with antibiotics alone. The other three with prosthetic
valve brucella endocarditis were treated with antibiotics and
valve replacement. Details of antibiotic therapy are shown in
Table 1. The indications for valve replacement were failure of
medical treatment in one patient (number 3; vegetations devel-
oped while he was receiving antibiotics), and brucella prosthetic
valve endocarditis in the other two. The duration of antibiotic
treatment was between 10 weeks and 20 weeks. Surgery on the
three patients was carried out 4 days, 10 days, and 11 weeks,
respectively, after starting antibiotic treatment.
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All patients were followed up in the clinic. The duration of
follow-up ranged between 10 months and 15 months. During
follow-up, no recurrences were observed.
Endocarditis is a rare complication of brucellosis, occurring
in less than 2% of cases [3]. In a recent review of the English and
French language literature since 1900, only 108 cases were
reported [5]. Brucellosis is endemic in Qatar; however, despite
this, only four cases of brucella endocarditis have been diag-
nosed during the last 15 years. Brucella melitensis and B. abortus
are the most frequently isolated species. Brucella endocarditis
produces highly destructive lesions of the valve structure [3];
this might explain the high fatality rate for brucella endocarditis.
Although the mortality rate for brucellosis is less than 1%,
endocarditis accounts for 80% of these deaths [4]. The com-
plication that is responsible for the majority of deaths is heart
failure [6]. Although published reports indicate that brucella
endocarditis usually involves normal native valves, and predo-
minantly the aortic valve in 75% of cases [3], it is interesting that
three of our patients had prosthetic valve brucella endocarditis,
and only one had native valve endocarditis. Brucella prosthetic
valve endocarditis is a very rare disease, with only 11 cases being
reported in the English literature [7–14]. Three of our patients
were males, in keeping with other reports [5]. The clinical
features in our patients were similar in many respects to those
reported by others [5,15]. Although heart failure is reported to
be common in these patients, being either present initially or
developing later on during the course of illness [5,7,15,16],
none of our patients had this complication. One of our patients
had hemiparesis, most probably secondary to an embolus
originating from valve vegetation. Diagnosis of brucella endo-
carditis may be difficult. Routine laboratory tests are not
helpful. Diagnosis depends on isolation of Brucella from blood
culture or cardiac tissue [15]. Blood cultures were positive in
three of our patients; B. melitensis grew in two, and in the third
the species was not specified. Culture of cardiac tissue taken
during surgery may be positive, despite prior antibiotic therapy
for up to 6 weeks [8]. In our series, cultures of cardiac tissue
were done in three patients. Brucella grew in the culture from
one patient who had only had 5 days of antibiotic treatment
before surgery. The two patients whose cultures were negative
had received 10 days and 11 weeks of antibiotic treatment
before surgery. The use of serologic tests to measure antibodies
against Brucella is helpful in the diagnosis of brucellosis. The
standard tube agglutination test (STA) is sensitive and specific. A
titer of 1 : 160 or more is presumptive evidence of brucella
infection [15]. Three patients in this series had a positive STA
test of 1 : 1280 or more. The fourth patient had repeatedly
negative serology. This patient’s blood grew Brucella species. A
false-negative STA test in patients with brucellosis can occur if
serum is not diluted beyond 1 : 320 owing to a prozone, or if
the infection is caused by B. canis, which does not react to the
antigen routinely used in the STA test [17]. It is unlikely thatTa
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the negative test in our patient is related to a prozone, since
serum is routinely tested to dilution beyond 1 : 320 in our
laboratory. Echocardiography, especially transesophageal echo-
cardiography, was very helpful in establishing the diagnosis of
brucella endocarditis in our patients by showing vegetations in
all patients, paravalvular leak in two patients, and an abscess in
one patient.
Uncertainty exists regarding many aspects of the treatment
of brucella endocarditis, including the appropriate antibiotic
combination and its duration, and the indications for surgery
and its timing [5,15,18,19]. A combination of antimicrobial
agents and valve replacement is the most accepted treatment
for brucella endocarditis [4,5]. Our first patient with native valve
brucella endocarditis was cured with medical treatment alone.
Antimicrobial agents can achieve sterilization of valve vegeta-
tions, and several cases of cure of native valve brucella endo-
carditis with medical therapy alone have been reported [15,20–
22]; however, because of the risk of relapse and the catastrophic
consequences of a relapsing infection, it is of the utmost
importance to carefully monitor the patient so that complica-
tions necessitating valve replacement are detected as early
as possible [18]. Medical therapy for brucella endocarditis
consists of a combination of antibiotics used for a long
period. The optimal combination and duration are unknown.
In our patients, different combinations of doxycycline,
rifampin, streptomycin and co-trimoxazole were used, so defi-
nite recommendations regarding the best combination could
not be made. A prolonged course of antibiotics to prevent
relapse seems to be advisable [15]. In different reports, the
duration of antibiotic therapy ranged from 6 weeks to
12 months, and in our series from 10 to 20 weeks. The decision
to stop treatment must be determined in each case after
thorough clinical observation [15]. The other three patients
with prosthetic valve endocarditis were treated with a
combination of antibiotics and valve replacement. Prosthetic
valve endocarditis caused by Brucella is cited as a primary
indication for surgery [8]; there is only one case report of cure
of brucella prosthetic valve endocarditis with antibiotics alone
[13]. Valve replacement may be performed during the active
phase of the disease, as the risk of recurrent infection in the new
prosthesis is low [5,23], as was the case in two of our patients.
The outcome was good in our series, which may be because
none of our patients had heart failure during the course of their
illness.
In conclusion, brucella endocarditis remains a rare but serious
complication of brucellosis. In our region, brucella endocarditis
should be seriously considered in the differential diagnosis of
patients with abnormal valves presenting with endocarditis,
especially in those at risk for brucellosis. Brucella endocarditis
of native valves may be treated with antibiotics alone, with
careful monitoring for complications. A prolonged course of
antibiotics is necessary. Brucella prosthetic valve endocarditis
should be treated with a combination of antibiotics and valve
replacement. Early surgical intervention during the active phase
of infection is safe, since the risk of infection of the new
prosthesis is low.
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Staphylococcus lugdunensis is a coagulase-negative staphylococcus
(CoNS) with the capacity to cause opportunistic infections in
humans. However, infections involving S. lugdunensis typically
resemble those associated with S. aureus in terms of the viru-
lence of the organism and the clinical course of infection, which
is often highly destructive [1,2]. Clinical case reports of infec-
tion caused by this organism include native valve endocarditis,
peritonitis, vertebral osteomyelitis and catheter-related infec-
tion but it has not previously been reported as a cause of
ventriculoperitoneal (VP) shunt infection [1–3]. S. epidermidis
is the most common cause of cerebrospinal fluid (CSF) shunt
infections, causing more than 50% of cases in one series [4]. The
affinity of S. epidermidis for medical devices, such as VP shunts,
has been attributed to its ability to adhere to plastics, with the
subsequent formation of biofilm which can reduce efficacy of
treatment and cause persistence of infection [5]. Biofilm for-
mation is believed to be mediated via the intercellular adhesin
gene cluster (ica), which is found more frequently in invasive S.
epidermidis isolates than contaminating strains [5,6]. This report
describes a case of VP shunt infection caused by S. lugdunensis.
In contrast to the usual indolent, subacute presentation of
S. epidermidis VP shunt infection, this case presented acutely
in a manner akin to a S. aureus infection. The association of
S. lugdunensis with a VP shunt infection prompted a search for
biofilm-forming ability which could be important for the
pathogenicity of this organism. Since S. lugdunensis can cause
aggressive infections, and shares some virulence factors with S.
aureus, the causative strain was also investigated for hemolysin
production and homologues of the global regulatory locus agr
(accessory gene regulator) which regulates virulence factor
production in S. aureus [7].
A 74-year-old male was referred for management of normal
pressure hydrocephalus. The patient had experienced increasing
problems with walking, urinary incontinence, memory loss and
loss of inhibition for 1 year prior to presentation. A computed
tomography (CT) scan was performed and showed ventricu-
lomegaly out of proportion to his cerebral atrophy. In 1996, the
patient underwent insertion of a VP shunt and was discharged
7 days after the procedure, without any immediate postopera-
tive problems.
Seven days later the patient was readmitted with abdominal
pain and sweating. The pain was right-sided, affecting the upper
quadrant and was exacerbated by deep inspiration. On admis-
sion, the patient appeared ill and was pyrexic (37.9 8C). Per-
ipheral white cell count was 17.5 109/L. Intra-abdominal
sepsis was suspected and a CT scan confirmed the presence of a
small subphrenic collection and associated pleural effusion. The
shunt was removed and the patient started empirically on
intravenous vancomycin, cefuroxime and rifampicin. At the
time of surgery, the scalp incision was opened first, and the
ventricular tip and a specimen of CSF sent for microscopy and
culture. The abdominal wound was then opened and, on
removal of the peritoneal catheter, purulent fluid emerged
from the abdominal cavity. Specimens of pus and the peritoneal
catheter were sent for culture. Postoperatively, the patient made
a good recovery and intravenous vancomycin with rifampicin
was continued for 1 week. A further 1 week of oral ciproflox-
acin and rifampicin was prescribed and the patient was dis-
charged well. A penicillin was not prescribed because of a
history of allergy.
Initial microscopy and Gram stain of the CSF showed 6/mm3
red blood cells, 6/mm3 white blood cells and scanty
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